Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
Status:
Recruiting
Trial end date:
2021-11-15
Target enrollment:
Participant gender:
Summary
The primary objective of the trial is to confirm the efficacy of glepaglutide in reducing
parenteral support volume in patients with short bowel syndrome.
Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.